Original article:  
Correlation of VEGF expression with prognostic factors of breast carcinoma  
Dr. Jhuma Nandi¹, Dr. Moumita Maiti², Dr. Neepamanjari Barman³, Dr. Moumita Paul⁴, Dr. Sreepurna Medda⁵, Prof. Sushil Ranjan Ghosal⁶, Prof. Ranu Sarkar ⁷ 

Abstract:  
Background: Breast carcinoma is the most common malignant tumour and leading cause of cancer death among women worldwide. VEGF being a powerful mediator of angiogenesis, plays a major role in local growth as well as metastasis of many solid tumours including breast carcinoma. Objective: This study aimed to evaluate the significance of VEGF expression in breast cancer and its correlation with prognostic parameters. Materials and methods: This study was conducted over a period of one year (February 2015 to January 2016). VEGF expression was evaluated in 57 histologically diagnosed cases of breast carcinoma with known ER and HER-2/neu status. Result: Among 57 cases 52(91.2%) were positive for VEGF. Positive ER expression was seen in 39 cases which is 64.8% of total cases. 54% of the total cases were positive for HER-2/neu. VEGF expression was positively correlated (P value <0.05) with tumour grade, tumour size and negatively correlated with ER (p<0.005) and HER-2/neu (p<0.005). Significant correlation also found with tumour type (p<.005). Conclusion: Considering the observations of the current study, it can be concluded that VEGF may play a crucial role in the pathogenesis of breast carcinoma and has a positive correlation with biologically aggressive tumour. So consideration of this biomarker (VEGF) is to be regarded as a prognostic parameter and critical evaluator of targeted chemotherapy.

Introduction:  
Breast cancer is the second most common cancer in the world and by far the most frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 2012, according to globocan (WHO). Highest number of deaths due to breast carcinoma (70218 women in the year2012) was reported from India¹. Angiogenesis has been shown to be a critical aspect of tumour growth and metastasis²⁴. The induction of angiogenesis by a tumour is a controlled process, influenced by angiogenic and angiostatic factors which involve a complex interaction between tumour and endothelial cells⁴⁶. Among the many reported angiogenic factors, vascular endothelial growth factor (VEGF) is the most powerful endothelial cell specific mitogen that plays a key role in the complicated process of angiogenesis. VEGF also known as vascular permeability factor, is a glycoprotein of 32-42 kDa. The VEGF family currently includes six known members: VEGF-A (commonly known as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor⁷⁹. VEGF activates tyrosine kinase receptors, VEGFR-1 (also referred to as FLT1) and VEGFR-2 (or KDR) located in the endothelium, which leads to stimulation of endothelial migration, proliferation, permeability,

1. Dr. Jhuma Nandi, Junior Resident, Department Of Pathology, NRS Medical College, Kolkata.  
2. Dr. Moumita Maiti  
3. Dr. Neepamanjari Barman  
4. Dr. Moumita Paul  
5. Dr. Sreepurna Medda, Demonstrator, Department Of Pathology, NRS Medical College, Kolkata.  
6. Prof. Sushil Ranjan Ghosal, Professor and Head, Department Of Surgery, NRS Medical College, Kolkata.  
7. Prof. Ranu Sarkar, Professor and Head, Department Of Pathology, NRS Medical College, Kolkata.  

Correspondence to: Dr. Moumita Maiti, Assistant Professor, Department Of Pathology, NRS Medical College, Kolkata. Address: Rajkumari Apartment, 6 Dr. Meghnad Saha Road, Chhatakal, Dum Dum, Kolkata 700074, Email: moumitapath11@gmail.com.
Correlation of VEGF expression with prognostic factors of breast carcinoma

Recent evidence suggests that VEGF not only plays a role in inducing angiogenesis but also promotes the survival of new vessels formed within the tumour.

A large number of studies conducted all over the world demonstrated that VEGF could be used as an indicator of significant poor outcome in patients of breast carcinoma.[12-14]. Therefore, the current study tries to find the expression of VEGF and its correlation with other prognostic parameters of breast carcinoma as a possible explanation for the aggressive behaviour of this tumour.

Materials and Methods:

It was a cross-sectional observational study conducted in the Department of Pathology in collaboration with the Department of General Surgery of NRS Medical College and hospital, Kolkata over a period of one year from February 2015 to January 2016. Study population included 57 cases of breast carcinoma, subjected to modified radical mastectomy (MRM).

Histopathology: Tissue slices are taken from primary tumours and axillary lymph nodes of properly fixed MRM specimen and processed. Sections (4-5 micron) were stained with routine Hematoxylin-eosin stain for histopathological examination.

Immunohistochemistry: Immunohistochemical stain (VEGF) in the sections (2-3 micron) prepared from the same block following a standard streptavidin-biotin-peroxidase technique. Rabbit monoclonal antibody for VEGF was used.

VEGF scoring: The criteria for positive immunoreaction are granular cytoplasmic positivity. Both intensity and percentage score was done (as shown in respective tables below) and final score was obtained by summation of percentage and intensity score.

Percentage score:

<table>
<thead>
<tr>
<th>Score</th>
<th>Staining pattern</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score 0</td>
<td>none of the cells revealed positivity for the marker</td>
</tr>
<tr>
<td>Score 1</td>
<td>Up to 10% of the tumour cells are stained</td>
</tr>
<tr>
<td>Score 2</td>
<td>Up to 25% of the tumour cells are stained positive</td>
</tr>
<tr>
<td>Score 3</td>
<td>Up to 50% of tumour cells are stained positive</td>
</tr>
<tr>
<td>Score 4</td>
<td>More than 50% of tumour cells are stained positive</td>
</tr>
</tbody>
</table>

Intensity score:

<table>
<thead>
<tr>
<th>Score</th>
<th>Staining pattern</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score 0</td>
<td>No staining</td>
</tr>
<tr>
<td>Score 1</td>
<td>Weak</td>
</tr>
<tr>
<td>Score 2</td>
<td>Moderate staining</td>
</tr>
<tr>
<td>Score 3</td>
<td>Strong staining</td>
</tr>
</tbody>
</table>

Final score:

<table>
<thead>
<tr>
<th>Score</th>
<th>Staining pattern</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>0-1</td>
</tr>
<tr>
<td>Weak</td>
<td>2-3</td>
</tr>
<tr>
<td>Moderate</td>
<td>4-5</td>
</tr>
<tr>
<td>Strong</td>
<td>6-7</td>
</tr>
</tbody>
</table>

Results of ER and HER-2/neu expression were noted from departmental records.

Statistical analysis: All data were analysed with applicable statistical tests using SPSS software and P value <0.05 was considered significant.

Ethical clearance: Prior the submission, the study was approved by the ethics committee of NRS Medical College, Kolkata

Result:

Out of total 57 cases 52 (91.2%) cases showed widespread cytoplasmic VEGF expression (table:1). All cases were female except one male patient. Strong VEGF was noted among the higher percentage (53%) of poorly differentiated (grade 3) breast carcinoma and it was positively correlated (Rho=0.290, p=0.02). Tumour size (Chart: 3) was also well correlated (rho value: 0.375) to immunoexpression of vascular endothelial growth factor with a P value of 0.004.

In case of tumour stage (Table: 2), 21.7% of tumours having stage III or more showed strong expression of VEGF, whereas only 9% of the stage II tumours were detected as strongly positive. Though stage of the tumour was positively correlated (rho value: 0.071) with VEGF expression but statistically it was not significant (p>0.05). Expression of ER (chart: 2) and HER-2/neu (Table: 3) showed negative correlation with VEGF which is statistically significant (P value<0.005).

Among 57 cases of breast carcinoma, 48 cases was invasive carcinoma of no special type (NOS) which accounted for 84.25% of total case and 18 among them had in situ component as well. Lobular, medullary and mucinous metaplastic type accounted for 7%, 3.5%, 1.75% and 3.5% of total cases respectively. Statistically significant correlation (P value <0.0001, Mann-Whitney test) among histological type of breast carcinoma and vascular endothelial growth factor expression was noted (table no: 1). However, we did not find any statistically significant correlation among axillary lymph node status and age of patient.
**Table, Charts & Figures**

**Table 1** - Expression of VEGF in different histological type of Breast carcinoma

<table>
<thead>
<tr>
<th>Histological type of breast carcinoma</th>
<th>VEGF Expression</th>
<th>Test of significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>Weak</td>
</tr>
<tr>
<td>Invasive carcinoma , NOS</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td>Invasive carcinoma NOS+ DCIS</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Lobular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleomorphic lobular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulo-lobular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive carcinoma with medullary features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metaplastic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grand total</td>
<td>5</td>
<td>26</td>
</tr>
</tbody>
</table>

NOS: No special type, DCIS: Ductal carcinoma in situ; p value - <0.0001(Mann-Whitney test)

**Table No: 2** – Expression of VEGF with stage of Breast carcinoma

<table>
<thead>
<tr>
<th>Stage of breast carcinoma</th>
<th>VEGF Expression</th>
<th>Test of significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>weak</td>
</tr>
<tr>
<td>III or more</td>
<td>4</td>
<td>21</td>
</tr>
<tr>
<td>II</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Grand Total</td>
<td>5</td>
<td>26</td>
</tr>
</tbody>
</table>

Rho= 0.071
P >0.05

**Table: 3** - Expression of VEGF in correlation with HER-2/neu

<table>
<thead>
<tr>
<th>HER-2/neu</th>
<th>VEGF Expression</th>
<th>Test of significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Negative</td>
<td>weak</td>
</tr>
<tr>
<td>Negative</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Positive</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td>Grand Total</td>
<td>5</td>
<td>26</td>
</tr>
</tbody>
</table>

Rho- 0.470
P <0.05

**Chart 1** - Expression of VEGF with grades

**Chart 2** - Correlation of VEGF Expression with ER
Correlation of VEGF expression with prognostic factors of breast carcinoma

**Discussion:**
Causation of breast carcinoma is multifactorial and angiogenesis has a pivotal role\textsuperscript{15}. The biology of breast carcinoma remains poorly understood as the knowledge about individual prognostic factors provides limited information\textsuperscript{16}. Inspite of a huge number of studies role of anti VEGF therapy is still debatable in case of breast cancer\textsuperscript{17}.

In our study VEGF was expressed in 91.2\% of breast carcinoma which was concordant with other previous studies by Vogl G et al (98\% VEGF positivity)\textsuperscript{20}, Anca Maria Cîmpean et al (87.15\%)\textsuperscript{21} and Adams J et al (80\%)\textsuperscript{18}. Whereas studies by Rivkin SE et al. showed very low expression (37\%)\textsuperscript{19}.

Presence of significant positive correlation between grade of breast carcinoma (chart: 1) and VEGF...
expression has been also shown by other researchers in different studies which explain the role of VEGF gene in tumour angiogenesis and tumour progression\textsuperscript{18,20,22,25}.

From chart no: 3, it has been clearly shown that T-stage of breast carcinoma (tumour size) is positively correlated with VEGF expression (p value : $<$0.005) and other investigators also found similar result\textsuperscript{20,25}. Adams J et al\textsuperscript{18} and Granato AM et al\textsuperscript{22} has reported that there is a significant negative correlation between VEGF and ER expression (chart no: 2) which is similar with our study findings (rho: -0.470, p-.002). Though many of the researchers\textsuperscript{20, 23} have failed to show any association between angiogenesis and HER2, we have noticed an association of HER2 and angiogenesis like Blackwell KL et al\textsuperscript{24} and a significant correlation with histological type like Cimpean A M et al\textsuperscript{21}.

**Conclusion:**

From the observations of our study it can be concluded that VEGF has the potential to be considered as an important prognostic parameter in breast carcinoma. Targeted therapy against it may be beneficial for the patients specially, who are triple negative and have no specific treatment other than chemotherapy. As it was a time bound study of relatively small numbers of cases with limited scope of follow up, a wider evaluation involving large no of cases provided with proper follow up facility is recommended to validate its therapeutic efficacy.

**Conflict of interest:** None declared

**Author’s contribution:**

Data gathering and idea owner of this study: Nandi J, Maiti M, Barman N, Study design: : Nandi J, Maiti M, Barman N, Paul M, Medda S, Ghosal SR 


Writing and submitting manuscript: Nandi J, Maiti M, Barman N, Paul M, Sarkar R 

Editing and approval of final draft: Nandi J, Maiti M, Barman N, Paul M, Medda S, Ghosal SR,

**References:**


Correlation of VEGF expression with prognostic factors of breast carcinoma


24. Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. *Clin Cancer Res*.2004;10:4083–4088. [http://clincancerres.aacrjournals.org/content/10/12/4083.long](http://clincancerres.aacrjournals.org/content/10/12/4083.long)